Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression

Biochemical and Biophysical Research Communications

Volumn 309, Issue 1, 2003, Pages 126-134

  Schnier, Joachim B ^a   Nishi, Kayoko ^a   Monks, Anne ^b   Gorin, Fredric A ^a   Bradbury, E Morton ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAIC FREDERICK INC   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Brain glycogen phosphorylase; Cancer; Cell cycle; Colony stimulating factor ; CP 91,149; Glioma; Tumor

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; CP 91149; CYCLIN E; ENZYME INHIBITOR; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA MICROARRAY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GLYCOGEN METABOLISM; GLYCOGENOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST;

EID: 0041734885     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01542-0     Document Type: Article

References (36)

1. O. Warburg, The metabolism of tumors, Constable London, 1930.
2. Mathupala S.P., Rempel A., Pedersen P.L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J. Bioenerg. Biomembr. 4:1997;339-343.
3. Bannasch P., Klimek F., Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J. Bioenerg. Biomembr. 4:1997;303-313.
4. Johnson L.N. Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J. 6:1992;2274-2282.
5. Pedersen B.A., Cheng C., Wilson W.A., Roach P.J. Regulation of glycogen synthase. Identification of residues involved in regulation by the allosteric ligand glucose-6-P and by phosphorylation. J. Biol. Chem. 275:2000;27753-27761.
6. Newgard C.B., Hwang P.K., Fletterick R.J. The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem. Mol. Biol. 24:1989;69-99.
7. Shimada S., Maeno M., Akagi M., Hatayama I., Sato T., Sato K. Immunohistochemical detection of glycogen phosphorylase isoenzymes in rat and human tissues. Histochem. J. 18:1986;334-338.
8. Sato K., Sato T., Morris H.P., Weinhouse S. Carcinofetal alterations in glycogen phosphorylase isozymes in rat hepatomas. Ann. NY Acad. Sci. 259:1975;273-286.
9. Newgard C.B., Littman D.R., van Genderen C., Smith M., Fletterick R.J. Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, comparison with the human liver and muscle isozymes. J. Biol. Chem. 263:1988;3850-3857.
10. Shimada S., Tashima S., Yamaguchi K., Matsuzaki H., Ogawa M. Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase. Exp. Clin. Cancer Res. 1:1999;111-118.
11. Wilson K.S., Roberts H., Leek R., Harris A.L., Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 161:2002;1171-1185.
12. Schnier J.B., Kaur G., Kaiser A., Stinson S.F., Sausville E.A., Gardner J., Nishi K., Bradbury E.M., Senderowicz A.M. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. 454:1999;100-104.
13. Kaiser A., Nishi K., Gorin F.A., Walsh D.A., Bradbury E.M., Schnier J.B. The cyclin-dependent kinase inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys. 386:2001;179-187.
14. Oikonomakos N.G., Schnier J.B., Zographos S.E., Skamnaki V.T., Tsitsanou K.E., Johnson L.N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275:2000;34566-34573.
15. Elliott L.H., Wilkinson S.E., Sedgwick A.D., Hill C.H., Lawton G., Davis P.D., Nixon J.S. K252a is a potent and selective inhibitor of phosphorylase kinase. Biochem. Biophys. Res. Commun. 17:1990;148-154.
16. Reddy S., Aggarwal B.B. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett. 34:1994;19-23.
17. Heng M.C., Song M.K., Harker J., Heng M.K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol. 143:2000;937-949.
18. Martin W.H., Hoover D.J., Armento S.J., Stock I.A., McPherson R.K., Danley D.E., Stevenson R.W., Barrett E.J., Treadway J.L. Discovery of human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;1776-1781.
19. Oikonomakos N.G., Skamnaki V.T., Tsitsanou K.E., Gavalas N.G., Johnson L.N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Struct. Fold. Des. 8:2000;575-584.
20. Rath V.L., Ammirati M., Danley D.E., Ekstrom J.L., Gibbs E.M., Hynes T.R., Mathiowetz A.M., McPherson R.K., Olson T.V., Treadway J.L., Hoover D.J. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7:2000;677-682.
21. Tobey R.A., Crissman H.A. Cell-cyle analysis in 20 minutes. Science. 184:1974;1297-1298.
22. Ignacio P.C., Baldwin B.A., Vijayan V.K., Tait R.C., Gorin F.A. Brain isozyme of glycogen phosphorylase: immunohistological localization within the central nervous system. Brain Res. 529:1990;42-49.
23. Gorin F.A., Ignacio P., Gelinas R., Carlsen R. Abnormal expression of glycogen phosphorylase genes in regenerated muscle. Am. J. Physiol. 257:1989;C495-C503.
24. Schnier J.B., Nishi K., Goodrich D.W., Bradbury E.M. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc. Natl. Acad. Sci. USA. 93:1966;5941-5946.
25. Layzer R.B., Rowland L.P., Ranney H.M. Muscle phosphofructokinase deficiency. Arch. Neurol. 17:1967;512-523.
26. Van Handel E. Estimation of glycogen in small amounts of tissue. Anal. Biochem. 11:1965;256-265.
27. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A.et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
28. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1990;1113-1118.
29. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81:1989;1088-1092.
30. Pines J., Hunter T. Human cyclin A is adenovirus E1A-associated protein p60 behaves differently from cyclin B. Nature. 346:1990;760-763.
31. Zaharevitz D.W., Holbeck S.L., Bowerman C., Svetlik P.A. COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. J. Mol. Graph. Model. 20:2002;297-303.
32. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:2000;227-235.
33. Rousset M., Chevalier G., Rousset J.P., Dussaulx E., Zweibaum A. Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma cell lines in culture. Cancer Res. 39:1979;531-534.
34. Rousset M., Dussaulx E., Chevalier G., Zweibaum A. Growth-related glycogen levels of human intestine carcinoma cell lines grown in vitro and in vivo in nude mice. J. Natl. Cancer Inst. 65:1980;885-889.
35. DharMascareno M., Chen J., Zhang R.H., Carcamo J.M., Golde D.W. Granulocyte-macrophage colony-stimulating factor signals for increased glucose transport via phosphatidylinositol 3-kinase- and hydrogen peroxide-dependent mechanisms. J. Biol. Chem. 278:2003;11107-11114.
36. Tu J., Karasavvas N., Heaney M.L., Vera J.C., Golde D.W. Molecular characterization of a granulocyte macrophage-colony-stimulating factor receptor alpha subunit-associated protein, GRAP. Blood. 96:2000;794-799.